Immunoassay in R&D Market to grow at a CAGR of 7.63% during 2025 to 2035; Driven by Rising Demand for Research Diagnostics and Increasing Adoption of ELISA Technologies

Market Highlights

The In the Immunoassay in R&D market, the Enzyme-Linked Immunosorbent Assay (ELISA) stands out as the largest segment. was estimated at 11.53 USD Billion in 2024. The industry is projected to grow from 12.54 USD Billion in 2025 to 25.99 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 7.63% during the forecast period 2025 - 2035.

 Immunoassays incorporate a variety of different labels for the detection of antibodies and antigens. These labels are generally chemically linked or conjugated to the desired antibody or antigen.

The increasing incidence of chronic and infectious diseases, growing research and development investment (R&D) activities, and technological advancements are the major factors boosting the growth of the market. Despite the drivers, the high cost of immunoassay procedures and the high price of immunoassay systems constrain the growth of the market.

Segment Analysis

The global immunoassay in R&D market has been segmented into type, application, and end user. By type, the market has been segmented into Enzyme-Linked Immunosorbent Assay (ELISA), Enzyme-Linked Immunospot Assay (ELISpot), Radioimmunoassay (RIA), Chemiluminescence (CLIA), Fluoroimmunoassay, and Others.

On the basis of application, the market has been segmented into infectious diseases, cancer research, endocrinology, autoimmune diseases, and others. By end-user, the market has been segmented pharmaceutical and biotechnology companies, academic institutions and laboratories, and others

Market Players

Market Research Future (MRFR) recognizes the following companies as the key players in the global immunoassay in R&D market that includes Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), Siemens Healthineers (Germany), Becton, Dickinson and Company (US), Danaher Corporation (US), bioMérieux Inc. (France), Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Sysmex Corporation (Japan), and Abcam plc (United Kingdom).

Regional Analysis

Geographically, the Americas is expected to dominate the global immunoassay in R&D market. The market growth is attributed to the increasing number of research projects in laboratories, growing adoption of advanced technology in research, and the growing prevalence of several diseases. The European market for immunoassay in R&D is expected to be the second-largest market due to the growing adoption in diagnostic measures is expected to boost the growth of the market in this region.

Moreover, the companies operating in the market are particularly focusing on mergers and acquisition which is expected to support the market growth. Asia-Pacific is estimated to be the fastest growing market due to the developing healthcare infrastructure and increasing disposable income.

In addition to this, improving healthcare infrastructure has increased the number of research activities in the region. Moreover, in the Asia-Pacific region, South Korea accounted for a market share of 10.1% in 2024. Furthermore, the market in the Middle East & Africa is expected to witness steady growth due to limited access to healthcare facilities.

Key Findings of the Study:

• Technological advancements are propelling the development of more sensitive and specific immunoassays.


• The shift towards multiplexing is enhancing the efficiency of diagnostic testing in clinical settings.


• Collaboration and innovation among key players are fostering rapid advancements in assay technologies.


• Rising demand for point-of-care testing and increased research funding are major drivers fueling market expansion.